Literature DB >> 638406

Two regimes with the same TDF but differing morbidity used in the treatment of stage III carcinoma of the cervix.

K Singh.   

Abstract

As an alternative to five daily fractions per week, one large fraction per week has been used to treat patients with stage III carcinoma of the cervix. This regime was greatly appreciated by our village women who could attend for weekly treatment from their homes. The weekly dose was matched with our previously acceptable daily fractionation using NSD, TDF and CRE values. In 24 patients the early reactions and tumour response were acceptable. Late rectal complications commencing seven months after treatment have, however, developed in all surviving patients with the new regime. The complications have been far more severe than those of a matched group of 24 patients treated with daily fractions and the schedule using one fraction per week has been abandoned. "Iso-effective" doses for the two techniques were selected from the NSD, TDF and CRE tables. This study clearly indicates that for one fraction per week the doses predicted are not "iso-effective" as far as the normal tissues of the pelvis are concerned.

Entities:  

Mesh:

Year:  1978        PMID: 638406     DOI: 10.1259/0007-1285-51-605-357

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  3 in total

Review 1.  The first James Kirk memorial lecture. What next in fractionated radiotherapy?

Authors:  J F Fowler
Journal:  Br J Cancer Suppl       Date:  1984

2.  Estimation of α/β for late rectal toxicity based on RTOG 94-06.

Authors:  Susan L Tucker; Howard D Thames; Jeff M Michalski; Walter R Bosch; Radhe Mohan; Kathryn Winter; James D Cox; James A Purdy; Lei Dong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-03-04       Impact factor: 7.038

3.  Preoperative radiation therapy for clinically resectable adenocarcinoma of the rectum.

Authors:  W M Mendenhall; R R Million; K I Bland; W W Pfaff; E M Copeland
Journal:  Ann Surg       Date:  1985-08       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.